致病性 Th17 细胞是 AChR 肌萎缩症患者使用他克莫司的潜在治疗靶点。

IF 2.9 4区医学 Q3 IMMUNOLOGY

Journal of neuroimmunology Pub Date : 2024-10-09 DOI:10.1016/j.jneuroim.2024.578464

Yingkai Li , Pei Chen , Xin Huang , Hao Huang , Qian Ma , Zhongqiang Lin , Li Qiu , Changyi Ou , Weibin Liu

{"title":"致病性 Th17 细胞是 AChR 肌萎缩症患者使用他克莫司的潜在治疗靶点。","authors":"Yingkai Li , Pei Chen , Xin Huang , Hao Huang , Qian Ma , Zhongqiang Lin , Li Qiu , Changyi Ou , Weibin Liu","doi":"10.1016/j.jneuroim.2024.578464","DOIUrl":null,"url":null,"abstract":"<div><div>In our study, we investigated the impact of tacrolimus (TAC) on CD4+ T cell subsets in 41 AChR-MG patients over 12 weeks. Twenty-seven patients were classified as the response group (RG) (improved myasthenia gravis composite scores ≥3), while 14 were non-response. We found that TAC treatment significantly reduced Th17 and pathogenic Th17 cells, along with IL-17 levels in RG, while Th1 and Tfh cells slightly decreased without affecting Th2 or Treg subsets. This indicates that TAC's clinical benefits may be due to its inhibitory effect on the Th17 response, enhancing our insight into its immunomodulatory mechanisms in MG management.</div></div>","PeriodicalId":16671,"journal":{"name":"Journal of neuroimmunology","volume":"396 ","pages":"Article 578464"},"PeriodicalIF":2.9000,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pathogenic Th17 cells are a potential therapeutic target for tacrolimus in AChR-myasthenia gravis patients\",\"authors\":\"Yingkai Li , Pei Chen , Xin Huang , Hao Huang , Qian Ma , Zhongqiang Lin , Li Qiu , Changyi Ou , Weibin Liu\",\"doi\":\"10.1016/j.jneuroim.2024.578464\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>In our study, we investigated the impact of tacrolimus (TAC) on CD4+ T cell subsets in 41 AChR-MG patients over 12 weeks. Twenty-seven patients were classified as the response group (RG) (improved myasthenia gravis composite scores ≥3), while 14 were non-response. We found that TAC treatment significantly reduced Th17 and pathogenic Th17 cells, along with IL-17 levels in RG, while Th1 and Tfh cells slightly decreased without affecting Th2 or Treg subsets. This indicates that TAC's clinical benefits may be due to its inhibitory effect on the Th17 response, enhancing our insight into its immunomodulatory mechanisms in MG management.</div></div>\",\"PeriodicalId\":16671,\"journal\":{\"name\":\"Journal of neuroimmunology\",\"volume\":\"396 \",\"pages\":\"Article 578464\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-10-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of neuroimmunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0165572824001838\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of neuroimmunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0165572824001838","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

在我们的研究中，我们调查了他克莫司（TAC）对 41 名 AChR-MG 患者的 CD4+ T 细胞亚群的影响，历时 12 周。其中 27 例患者被归为应答组（RG）（肌无力综合评分≥3 分），14 例为无应答组。我们发现，TAC治疗可明显减少RG中的Th17细胞和致病性Th17细胞以及IL-17水平，而Th1和Tfh细胞则略有减少，但不影响Th2或Treg亚群。这表明TAC的临床疗效可能是由于其对Th17反应的抑制作用，从而加深了我们对其在MG治疗中的免疫调节机制的了解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Pathogenic Th17 cells are a potential therapeutic target for tacrolimus in AChR-myasthenia gravis patients

In our study, we investigated the impact of tacrolimus (TAC) on CD4+ T cell subsets in 41 AChR-MG patients over 12 weeks. Twenty-seven patients were classified as the response group (RG) (improved myasthenia gravis composite scores ≥3), while 14 were non-response. We found that TAC treatment significantly reduced Th17 and pathogenic Th17 cells, along with IL-17 levels in RG, while Th1 and Tfh cells slightly decreased without affecting Th2 or Treg subsets. This indicates that TAC's clinical benefits may be due to its inhibitory effect on the Th17 response, enhancing our insight into its immunomodulatory mechanisms in MG management.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of neuroimmunology 医学-免疫学

CiteScore

6.10

自引率

3.00%

发文量

154

审稿时长

37 days

期刊介绍： The Journal of Neuroimmunology affords a forum for the publication of works applying immunologic methodology to the furtherance of the neurological sciences. Studies on all branches of the neurosciences, particularly fundamental and applied neurobiology, neurology, neuropathology, neurochemistry, neurovirology, neuroendocrinology, neuromuscular research, neuropharmacology and psychology, which involve either immunologic methodology (e.g. immunocytochemistry) or fundamental immunology (e.g. antibody and lymphocyte assays), are considered for publication.